title: Comparison of clinical and laboratory parameters in patients with end-stage renal failure in the outcome of chronic glomerulonephritis and patients with end-stage renal failure in the outcome of other diseases.
abstract: BACKGROUND
  frequent complications of hemodialysis treatments are coagulation disorders. This is due to activation of the coagulation of blood flow in the interaction with a dialysis membrane material vascular prostheses and extracorporeal circuit trunks. In addition, in hemodialysis patients receiving heparin for years, there is depletion of stocks in endothelial cells in tissue factor inhibitor, inhibits the activity of an external blood clotting mechanism.
  
  
  OBJECTIVE
  the aim of our study was to evaluate the hemostatic system parameters in patients with end-stage renal failure, depending on the cause of renal failure.
  
  
  METHODS
  to evaluate the hemostatic system parameters in patients with end-stage renal failure, depending on the cause of renal failure and hemodialysis treatment duration conducted a study that included 100 patients observed in the department of chronic hemodialysis and nephrology hospital №1 Republican National Medical Center in the period of 2013-2016.
  
  
  RESULTS
  in patients with end-stage renal failure in the outcome of chronic glomerulonephritis, a great expression of activation of blood coagulation confirm increased the mean concentration of fibrinogen, whereas in the group, which included patients with end-stage renal failure in the outcome of other diseases, such is not different from the norm, and a higher rate of hyperfibrinogenemia, identified in 2/3 patients in this group.
  
  
  CONCLUSIONS
  it was revealed that the state of homeostasis in patients with end-stage renal failure in increasingly characterizes the level of fibrinogen and the activation of the hemostatic markers: soluble fibrin monomer complexes, D-dimers.
authors.affiliation: Federal State Autonomous Institution Of Higher Education "North-Eastern Federal University Named After M.K. Ammosov", Yakutsk, Russia.
authors.forename: J A
authors.initials: JA
authors.lastname: Popova
authors.affiliation: Federal State Autonomous Institution Of Higher Education "North-Eastern Federal University Named After M.K. Ammosov", Yakutsk, Russia.
authors.forename: V N
authors.initials: VN
authors.lastname: Yadrihinskaya
authors.affiliation: Federal State Autonomous Institution Of Higher Education "North-Eastern Federal University Named After M.K. Ammosov", Yakutsk, Russia.
authors.forename: M I
authors.initials: MI
authors.lastname: Krylova
authors.affiliation: Federal State Autonomous Institution Of Higher Education "North-Eastern Federal University Named After M.K. Ammosov", Yakutsk, Russia.
authors.forename: S S
authors.initials: SS
authors.lastname: Sleptsovа
authors.affiliation: Federal State Autonomous Institution Of Higher Education "North-Eastern Federal University Named After M.K. Ammosov", Yakutsk, Russia.
authors.forename: N V
authors.initials: NV
authors.lastname: Borisovа
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis*; D005921:Glomerulonephritis / Q000150:complications*; D006487:Hemostasis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D005340:Fibrinogen
keywords:  renal replacement therapy ;  terminal renal failure; hemostasis